The possibility of calculating optimal doses in combined medicinal product (Working hypothesis)
https://doi.org/10.37489/2587-7836-2024-1-23-26
EDN: RIPRNC
Abstract
The purpose of the study is a theoretical justification (working hypothesis) of a possible approach to calculating doses in a combined medicinal product containing 2 pharmaceutical substances. A mathematical model is proposed, which is a multiple regression equation from two variables, which is a square polynomial. The proposed model makes it possible to calculate the optimal doses of pharmaceutical substances in a combined drug by further differentiating the regression equation in partial derivatives. Two examples of dose calculation are presented.
About the Authors
I. B. Tsorin
FSBSI «Federal research center for innovator and emerging biomedical and pharmaceutical technologies»
Russian Federation
Russian Federation
Iosif B. Tsorin – PhD, Dr. Sci. (Biology), Leading Researcher of Laboratory of Circulation Pharmacology
Moscow
S. A. Kryzhanovskii
FSBSI «Federal research center for innovator and emerging biomedical and pharmaceutical technologies»
Russian Federation
Russian Federation
Sergey A. Kryzhanovskii – PhD, Dr. Sci. (Biology), Head of Laboratory of Circulation Pharmacology
Moscow
References
1. Dobrovolskiy AV. Approaches to clinical development of combination medicines in the Russian Federation and the Eurasian Economic Union in view of the requirements of the current legislation. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya = The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2019;9(1):14-27. (In Russ.). doi: 10.30895/1991-2919-2019-9-1-14-27.
2. Vrijens B, Antoniou S, Burnier M, et al. Current Situation of Medication Adherence in Hypertension. Front Pharmacol. 2017 Mar 1;8:100. doi: 10.3389/fphar.2017.00100.
3. Wirtz VJ, Kaplan WA, Kwan GF, Laing RO. Access to Medications for Cardiovascular Diseases in Low- and Middle-Income Countries. Circulation. 2016 May 24;133(21):2076-85. doi: 10.1161/CIRCULATIONAHA.115.008722.
4. Sylvester KW, Cheng JW, Mehra MR. Esomeprazole and aspirin fixed combination for the prevention of cardiovascular events. Vasc Health Risk Manag. 2013;9:245-54. doi: 10.2147/VHRM.S44265.
5. Roberts DN, Miner PB. Safety aspects and rational use of a naproxen + esomeprazole combination in the treatment of rheumatoid disease. Drug Healthc Patient Saf. 2011;3:1-8. doi: 10.2147/DHPS.S7329.
6. Devabhaktuni M, Bangalore S. Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives. Vasc Health Risk Manag. 2009;5(1):377-87. doi: 10.2147/vhrm.s3339.
7. McDonagh M, Peterson K, Thakurta Sg. Dana T. Drug class review: fixed dose combination drug products for the treatment of type 2 diabetes and hyperlipidemia: final report [internet]. Portland (OR): Oregon Health & Scienc University; 2007 Oct. PMID: 20496342.
8. Steinberg H, Anderson MS, Musliner T, et al. Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin. Vasc Health Risk Manag. 2013;9:273-82. doi: 10.2147/VHRM.S44330.
9. Rafales-Lamarka EE, Nikolaev VG. Some methods of planning and mathematical analysis of biological experiments. Kiev: Scientific Thought, 1971. (In Russ.)
Review
For citations:
Tsorin I.B., Kryzhanovskii S.A. The possibility of calculating optimal doses in combined medicinal product (Working hypothesis). Pharmacokinetics and Pharmacodynamics. 2024;(1):23-26. (In Russ.) https://doi.org/10.37489/2587-7836-2024-1-23-26. EDN: RIPRNC
Views:
157
Email this article 